ASCO 2026 reveals a CGT CDMO surge, with Parallel Mini-bioreactor demand up 210% and early-stage orders shifting to China CXO platforms. See what it means for outsourcing and procurement.

ASCO 2026 signals a surge in cell therapy CMO orders, driven by late-stage CAR-T and TCR-T demand. Discover what it means for CDMOs, bioreactor procurement, and CGT capacity planning.

ASCO 2026 reveals CGT CMO orders surging as bioreactor demand jumps with faster CAR-T and NK approvals. See what supply tightness and Q1 2027 lead times mean for buyers.

APEC Bio-Process Interface Standard (AP-BPIS-2026) is live — China-led bioprocess protocol now mandatory across 12 APEC economies. Boost export speed, cut compliance costs & future-proof biomanufacturing systems.

Bluepha's PHA tech achieves FDA Process Equivalence—key milestone for synthetic biology exporters, CGT & mRNA vaccine manufacturers seeking compliant, high-yield biomanufacturing solutions.

APEC Sets Smart Bio-Process Interface Standards: Discover how new OPC UA, digital twin, and batch data standards accelerate bioreactor exports and CDMO integration.

Humanoid Robotics + Bioprocess white paper launched at 2026 Zhongguancun Forum — introducing PM-BioLink v1.0 for AI-driven bioreactor interoperability.